nm23-H1蛋白在急性髓细胞白血病患者中的表达及其疗效

Expression of nm23-H1 protein in patients with acute myelocytic leukemia and its efficacy

目的探讨nm23-H1蛋白在急性髓细胞白血病(AML)患者中的表达及其疗效。方法 86例急性髓性白血病患者设为观察组,79例健康人群作为对照组。结果 86例AML患者免疫分型阳性表达率由高到低依次为CD33(94.17%)、MPO(86.05%)、CD13(77.91%);CD13+组患者血清nm23-H1蛋白表达情况显著高于CD13-组(t=3.641,P<0.001)。CD33+组患者血清nm23-H1蛋白表达情况显著高于CD33-组(t=2.699,P=0.008)。MPO+组患者血清nm23-H1蛋白表达情况显著高于MPO-组(t=3.402,P=0.001)。初治组患者、CR组、复发组血清nm23-H1蛋白表达显著高于对照组(P<0.05)。结论 AML免疫抗原CD13、CD33、MPO表达阳性患者血中nm23-H1蛋白呈现表达上调。

Objective To explore expression of nm23-H1 protein in patients with acute myelocytic leukemia（ AML） and its efficacy. Methods Eighty six patients with AML were selected as observation group,while 79 normal people were selected as control group. Results Positive expression rates of immune classification from high to low in 86 patients with AML were 94. 17% of CD33,86. 05% of MPO and 77. 91% of CD13. Expression of nm23-H1 protein in CD13＋group was significantly higher than that in CD13-group（ t = 3. 641,P〈0. 001）. Expression of nm23-H1 protein in CD33＋group was significantly higher than that in CD33-group（ t = 2. 699,P = 0. 008）. Expression of nm23-H1 protein in MPO＋group was significantly higher than that in MPO-group（ t = 3. 402,P= 0. 001）. Expressions of serum nm23-H1 protein in initial treatment group,CR group and recurrence group were significantly higher than control group（ P〈0. 05）. Conclusion In AML patients with positive expressions of immune antigen CD13,CD33 and MPO,expression of serum nm23-H1 protein is up-regulated.